1. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorder 5 (DSM-5). Arlington VA: American Psychiatric Association; 2013.
2. Barkely RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. New York: The Guilford Press; 2015.
3. Volk HE, Neuman RJ, Todd RD. A systematic evaluation of ADHD and comorbid psychopathology in a population-based twin sample. J Am Acad Child Adolesc Psychiatry 2005;44:768-775.
4. Dunn DW, Austin JK, Harezlak J, Ambrosius WT. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003;45:50-54.
5. Dunn DW, Austin JK. Differential diagnosis and treatment of psychiatric disorders in children and adolescents with epilepsy. Epilepsy Behav 2004;5(Suppl 3):S10-S17.
8. Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 2008;12:217-233.
9. Park JH, Choi HW, Yum MS, Ko TS, Shon SH, Kim HW. Relationship between aggravation of seizures and methylphenidate treatment in subjects with attention-deficit/hyperactivity disorder and epilepsy. J Child Adolesc Psychopharmacol 2018;28:537-546.
10. Salpekar JA, Mishra G. Key issues in addressing the comorbidity of attention deficit hyperactivity disorder and pediatric epilepsy. Epilepsy Behav 2014;37:310-315.
11. Stevens JR, Wilens TE, Stern TA. Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges. Prim Care Companion CNS Disord 2013;15. pii:PCC.12f01472
12. Reilly CJ. Attention deficit hyperactivity disorder (ADHD) in childhood epilepsy. Res Dev Disabil 2011;32:883-893.
13. Torres A, Whitney J, Rao S, Tilley C, Lobel R, Gonzalez-Heydrich J. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. Epilepsy Behav 2011;20:95-102.
14. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia 2017;58:522-530.
15. Fisher RS, Cross JH, D’Souza C, French JA, Haut SR, Higurashi N, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017;58:531-542.
16. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Washington DC: US Department of Health, Education, and Welfare Publication, National Institute of Mental Health; 1976.
17. Weiss M, Childress A, Nordbrock E, Adjei AL, Kupper RJ, Mattingly G. Characteristics of ADHD symptom response/remission in a clinical trial of methylphenidate extended release. J Clin Med 2019;8. pii:E461
18. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry 2009;48:511-518.
20. Park KJ, Kim HW. Clinical and neuropsychological factors associated with treatment response and adverse events of atomoxetine in children with attention-deficit/hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 2019;30:74-82.
21. Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007;49:498-502.
22. Hernandez J, Barragan E, Garza S. Efficacy of atomoxetine treatment in children with ADHD and epilepsy. Neuropediatrics 2006;37:THP12
23. Ravi M, Ickowicz A. Epilepsy, attention-deficit/hyperactivity disorder and methylphenidate: critical examination of guiding evidence. J Can Acad Child Adolesc Psychiatry 2016;25:50-58.